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Background: Current interventions for haemorrhoidal disease include traditional haemorrhoidectomy (TH) and
stapled haemorrhoidopexy (SH) surgery. However, uncertainty remains as to how they compare from a clinical,
quality of life (QoL) and economic perspective. The study is therefore designed to determine whether SH is more
effective and more cost-effective, compared with TH.
Methods/Design: eTHoS (either Traditional Haemorrhoidectomy or Stapled Haemorrhoidopexy for Haemorrhoidal
Disease) is a pragmatic, multicentre, randomised controlled trial. Currently, 29 secondary care centres are open to
recruitment. Patients, aged 18 year or older, with circumferential haemorrhoids grade II to IV, are eligible to take part.
The primary clinical and economic outcomes are QoL profile (area under the curve derived from the EuroQol Group’s 5
Dimension Health Status Questionnaire (EQ-5D) at all assessment points) and incremental cost per quality adjusted life
year (QALY) based on the responses to the EQ-5D at 24 months. The secondary outcomes include a comparison of the
SF-36 scores, pain and symptoms sub-domains, disease recurrence, complication rates and direct and indirect costs
to the National Health Service (NHS). A sample size of n =338 per group has been calculated to provide 90% power
to detect a difference in the mean area under the curve (AUC) of 0.25 standard deviations derived from EQ-5D
score measurements, with a two-sided significance level of 5%. Allowing for non-response, 400 participants will
be randomised per group. Randomisation will utilise a minimisation algorithm that incorporates centre, grade of
haemorrhoidal disease, baseline EQ-5D score and gender. Blinding of participants and outcome assessors is not
attempted.
Discussion: This is one of the largest trials of its kind. In the United Kingdom alone, 29,000 operations for haemorrhoidal
disease are done annually. The trial is therefore designed to give robust evidence on which clinicians and health
service managers can base management decisions and, more importantly, patients can make informed choices.
Trial registration: Current Controlled Trials ISRCTN80061723 (assigned 8 March 2010).
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The burden of the problem
Haemorrhoids are common in all age groups from mid-
teens onwards. In 2006 and 2007, approximately 25,000
haemorrhoidal procedures were performed in England
as hospital day-case or inpatient admissions, resulting in
significant calls on health service resources [1]. The treat-
ment of haemorrhoidal disease is directed at relieving its
related symptoms. Traditional surgical haemorrhoidectomy
(TH) involves excision of the haemorrhoidal cushions and
is generally advocated for symptomatic haemorrhoids of
grade III or IV. This traditional approach, whilst effective,
is however associated with severe pain.
Improved understanding of the pathogenesis of hae-
morrhoids [2], increasing belief in the importance of
preserving the anal cushions and greater awareness of
the complications associated with excisional haemorrhoi-
dectomy led to the invention of newer surgical procedures
including stapled haemorrhoidopexy.
Stapled haemorrhoidopexy (SH) was conceived over
15 years ago and was first described by Longo [Longo A:
Treatment of haemorrhoidal disease by reduction of
mucosa and haemorrhoidal prolapse with a circular
suturing device: a new procedure, unpublished]. Its
potential advantages over traditional surgery include a
reduction of operating time, hospital stay, time to return
to work and postoperative pain [3]. These features would
seem to make it attractive to patients and healthcare pro-
viders. Nevertheless, uncertainties around complication
rates, recurrence of symptoms and costs preclude its
widespread use across the National Health Service (NHS).
The decision to evaluate clinical and cost-effectiveness of
the two surgical treatments for haemorrhoids (stapled
haemorrhoidopexy and traditional haemorrhoidectomy)
There have been multiple randomised controlled trials
(RCTs) comparing SH with TH. These RCTs have been
analysed in two systematic reviews and a Health Tech-
nology Assessment (HTA) monograph [4-6]. The HTA
included a review of the clinical effectiveness data from
27 RCTs (n =2,279; 1,137 SH; 1,142 TH). When comparing
SH with TH, the authors revealed equivalent complication
and pain rates at day 21. However, SH patients had less
pain in the immediate post-operative period compared
with TH. Over the longer term, there was a significantly in-
creased rate of residual prolapse requiring re-intervention
with SH; however, there was no evidence of a difference in
the number of patients experiencing pain or bleeding
between SH and TH. The economic evaluations of the
two interventions reported in the HTA monograph found
that TH dominated SH, but it should be noted that TH
and SH had very similar costs and Quality of Adjusted Life
Years (QALYs). The additional cost of the stapling instru-
ment was largely, but not completely, offset by savings inoperating time and hospital stay. In terms of QALYs, the
improvements in quality of life due to lower pain levels in
the early post-operative period with SH were offset by
losses in quality of life as a result of the higher rate of
symptoms over the follow-up period. SH thus appears to
be associated with less pain in the immediate postopera-
tive period, but a higher rate of recurrence in the longer
term and increased need for further surgery. These find-
ings are based on data from small trials, all with methodo-
logical flaws, and providing limited data on quality of life
(or with respect to an economic interpretation, health
state utilities) in the early postoperative period. The study
by Thaha and colleagues reported similar findings [7].
There are, however, a number of potential limiting factors
in the applicability of this study. First, the SF-36 data used
to measure quality of life did not rule out substantial
differences, which only a larger trial would be able to
detect. Second, the stapling gun has subsequently under-
gone refinement (recruitment was completed in 2002).
Third, the trial was conducted prior to the stapling tech-
nique being well-established in the UK health care system.
Whilst there is a reasonable volume of work on grade
III and IV haemorrhoids, there is a paucity of clinical and
economic data regarding SH or TH for grade II haemor-
rhoids. Our group has conducted a RCT comparing rubber
band ligation (RBL) with SH for grade II haemorrhoids
using both clinical and economic outcomes [8]. This
showed a superior clinical effect of SH compared to RBL in
terms of recurrence of haemorrhoid symptoms. However
from a health economic standpoint, SH, when compared
with RBL could not be justified, even with a two-year
follow-up. The trend over a longer period, however,
suggested that the greater failure rate for RBL may
eventually reach a level that justified the increased cost
of SH. However, a larger trial with longer term follow-up
is needed to confirm this.
This small trial used similar outcome measures to
those being used in eTHoS and had a high return rate
over a median follow-up period of 36 months. Internal
reproducibility of the symptom score (the Haemorrhoid
Symptom Score) was also validated in this trial by re-
administration of questionnaires after an appropriate
wash-out period [9]. This symptom score measures
the presence, frequency and severity of key haemor-
rhoidal symptoms (prolapse, pain, bleeding, pruritis,
seepage and incontinence for flatus or faeces). These
symptoms are scored from 0 to 4 in each domain
(except for pain, which scores from 0 to 2). The Cleve-
land incontinence score [10] is a standard measure of
the degree of disturbance to life caused by incontinence.
While it is evident that many patients with haemorrhoids
have mild disturbance mainly related to flatus, the main
utility is in detecting any problems related to sphincter
injury as a result of surgery.
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ered, high quality, multicentre RCT comparing the
clinical and cost-effectiveness of SH compared with
TH. Patient reported health status will be observed
over the trial period as well as symptoms related to
haemorrhoids, general health and complications from
either procedure.
The aim of eTHoS is to assess whether SH is more
effective and cost-effective compared with traditional
excisional haemorrhoidectomy (TH) for people with
haemorrhoids (grade II, III and IV).
The primary objective is to compare patient reported
overall health related quality of life (measured using the
EQ-5D) over a period of 24 months.
The secondary objectives are to compare sub-domains
of health (SF-36 scores, pain and symptoms), disease
recurrence, complication rates, and direct and indirect
costs to the NHS, and cost-effectiveness (measured in
terms of incremental cost per QALY, where QALYs are
derived from responses to the EQ-5D).
Methods/Design
eTHoS is a pragmatic, multicentre, superiority, parallel
group trial comparing SH and TH.
Trial recruitment and allocation
In order to run the study according to the protocol, each
hospital centre participating in the eTHoS study will
require at least two members of staff to occupy two key
research roles. One research role is that of a (co-investi-
gating) colorectal consultant; the other will be a local
Recruitment Officer (RO) (for example, a nurse or junior
doctor). In exceptional circumstances the colorectal
consultant may perform both roles. At each centre
there may be more than one colorectal consultant
(co-investigator) who will be fully eTHoS-trained and
actively screening potential patients (for eligibility)
and subsequent recruitment onto the trial. At each
centre, one of these consultants will assume the lead-
ing role of local lead colorectal surgeon for eTHoS.
The RO will work with all of the named eTHoS
study colorectal surgeons and, along with the lead,
will administer the trial in accordance with the
protocol. A list of participating sites can be obtained
from the Chief Investigator, Professor Angus Watson
(angus.watson@nhs.net).
People considered for trial entry
Inclusion criteria include the following:
1. patients with circumferential haemorrhoids grade ii,
grade iii and iv,
2. patients aged 18 years or older and
3. written informed consent.Exclusion criteria include the following:
1. previous surgery for haemorrhoids (traditional or
stapled) (except rubber band ligation (rbl) or
haemorrhoidal artery ligation operation (halo));
2. previous surgical treatment for anal sphincter injury
repair, or symptomatic incontinence and peri-anal
sepsis;
3. known inflammatory bowel disease;
4. malignant gastrointestinal disease, within the last
five years;
5. medically unfit for surgery or for completion of the
trial; or
6. pregnant women.
Recruitment and administration of follow-up procedure
for eTHoS
Participating surgeons from each collaborating colorectal
surgical unit will identify patients referred to the hospital
for surgical treatment. Those patients meeting the eligi-
bility criteria will be invited to enter the trial. Patients
who accept the invitation to join the trial will be randomly
assigned to be treated by either SH or TH. Outcome
assessment will be at 1 week, 3 weeks and 6 weeks after
surgery and 12 months, 24 months and (subject to secur-
ing further funding) 60 months after randomisation. If
response to longer term follow-up (1 year or later) is lower
than anticipated, approaches to address this will be con-
sidered, and research ethics committee (REC) approval
will be sought if appropriate.
Recruitment procedure
Local procedures at the participating hospitals are differ-
ent and the timing and mode of approach to patients
and the consent process will vary to accommodate both
the variability at the sites and the needs of the patients.
Eligible patients will be identified in the clinic setting
by the colorectal surgeon or a suitably qualified trained
member of the local clinical team and noted in an
eTHoS log book. The colorectal surgeon will inform the
patient during this initial consultation about the differ-
ent treatments available for their condition as well as
giving information about the eTHoS study. As is normal
clinical practice, the colorectal surgeon will explain the
risks and benefits of all the treatment options.
Informed consent will be obtained from all participants.
The colorectal surgeon, or local trained clinical team
member, will give each potential participant the Patient
Information Sheet. This explains the rationale behind the
eTHoS study, as well as what taking part encompasses.
The colorectal surgeon, or locally trained clinical team
member, will then be on hand to answer any questions/
discuss the study with the potential participant during/im-
mediately after this consultation appointment or at home.
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detail the Patient Information Sheet (already given) during
this time. If the patient agrees to be contacted at home,
he/she may receive a telephone call from a local study
team member to discuss the trial. Patients who decide to
participate after telephone counselling can either send
their completed documents (consent form and baseline
questionnaire) through the post to the local study team at
their treating hospital or bring it with them if/when they
are returning to hospital for pre-op assessment or at the
time of the operation.
Patients who are able to make a decision to join the
study whilst they are at the clinic will be provided with
the eTHoS participant baseline questionnaire that com-
prises the EQ-5D, SF-36, Cleveland Incontinence Score
and Haemorrhoids Symptom Score. Contact details of
both the local and central team are provided on the
Patient Information Sheet. Patients who require more
time to consider participation in the study will be encour-
aged to contact either the local or central team if they
have any queries for which they would like clarification
before they return to hospital. The potential participant
will then be re-approached by a local clinical team
member prior to surgery. If a patient does not return
for pre-assessment (for example, if they live remotely
or due to local site procedures), then the patient can
return their signed consent form by post to their
recruiting site. The form will be counter-signed on
receipt by the local clinical team member. The patient
will be advised to contact the site staff by telephone for
further clarification or information if needed.
These arrangements will be individualised for each
centre. Following full written consent and baseline data
completion, patients will be randomised, as near to their
surgery as possible, to one of the two study groups in
equal proportion using the randomisation application at
the trial office. Patients who return their signed consent
forms by post will then complete the baseline question-
naire prior to surgery, to enable randomisation to take
place.
The outcome of the recruitment consultation(s) with
each potential eTHoS participant will be fully documented
in an eTHoS log book. For those who consent to partici-
pate, a copy of their signed consent form will be filed in
the patient’s hospital record. In addition, a copy will be
given to the participant, a copy will be held in the investi-
gator’s site file and the original will be retained by the trial
office.
For those patients who do not consent to participate,
an ‘Ineligible/Declined’ form will be completed by a local
clinical team member, detailing non-personal data, in-
cluding the reason(s) for the participant declining, or the
ineligibility criterion. These data will be recorded on the
study database.Follow-up procedure
The eTHoS patient follow-up will consist of a visit to
the hospital, approximately 6 weeks after surgery (range
allowed 4 to 8 weeks), for a clinical consultation and
assessment. At randomisation, both the participant and
the surgeon will be aware of the treatment random-
isation group. Data collected at all participant visits
(including the initial consultation/eligibility visit) will
be recorded in the first instance on paper case report
forms (CRFs) then entered onto the trial database via a
secure web portal.
The trial office will coordinate follow-up and data col-
lection in collaboration with the UK centres. The study
web portal will be the fulcrum of all trial documentation
and facilitate communication between study personnel.
The surgical form will be completed by the operating
surgeon. All participant-reported outcomes (PROs) (apart
from baseline) will be collected by postal questionnaires
administered from the trial office.
Additional clinic or hospital visits
Data on any additional hospital visits will be recorded
on the CRF completed when participants return for the
6-week clinical follow-up or in the patient reported
outcomes.
Participant withdrawal
Participants will remain on the trial unless they choose to
withdraw consent or if the principal investigator (PI), chief
investigator (CI) or trial office feel it is no longer appro-
priate for the participant to continue (that is, participant
becomes unable to complete the trial documentation).
The reason for the participant being withdrawn from the
trial will be recorded on the ‘withdrawal/change of status’
form, and if the participant is still willing to complete fol-
low up questionnaires and/or to have relevant outcome
data collected from NHS records, then the follow-up
process will continue.
Training
Training and support will be given in a standardised format
to both the colorectal surgeons and the ROs. Training, by a
member of the study team, will focus on the eTHoS trial
flowchart and the protocol. Training in physical baseline
and follow-up measurements will also be given to the ROs
if required. The colorectal surgeons and the ROs will use
standard study instruction manuals and documentation,
which will be provided by the study office, for reference
and support throughout. The study office will also be the
first point of contact for the colorectal surgeons and
the ROs in case of problems, concerns, adverse effects or
the need for advice. RO training days will also be held in a
variety of UK locations.
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It is envisaged that the duties of the principal local
investigator, co-investigating colorectal surgeons and the
ROs will be managed among them according to capacity
and in accordance with the eTHoS protocol.
Randomisation and allocation
Participants will be randomised to one of the two study
groups in equal proportion using a randomisation applica-
tion in the trial office. This randomisation application will
be available 24 hours a day, 7 days a week and has both an
Interactive Voice Response (IVR) telephone and web-
based interface. Randomisation will take place as near to
the time of surgery as possible using minimisation.
The minimisation algorithm [11] will use centre, grade
of haemorrhoidal disease (II, III or IV), baseline EQ-5D
score and gender.
Trial interventions
Eligible and consented participants will be placed on the
appropriate waiting list by the treating colorectal surgeon
or his/her designated team member. Participants will
receive the allocated intervention, either SH or TH. Each
centre’s participating surgeons must have undergone
appropriate recognised training for both stapled and
traditional haemorrhoid surgery. Ideally, this will have
included attendance at a ‘master class’. Surgery can be
performed by surgeons in training, either independently, if
signed off by their supervising consultant, or under the
direct supervision of their consultant. Pre- and post-
operative care is to follow the respective surgeon’s and
centres standard policies.
Baseline data and follow-up measurements are recorded
throughout the study on the eTHoS Case Report Forms
(CRF).
See Figure 1 for an overview of the trial.
Stapled haemorrhoidopexy
The patient will undergo stapled haemorrhoidopexy (SH).
Each centre must house experienced surgeons who have
undergone appropriate surgical training to perform SH.
• SH aims to correct haemorrhoidal prolapse by excising
a ring or ‘donut’ of tissue above the haemorrhoidal cush-
ions with immediate re-anastomosis of the mucosa using
staples. A secondary effect may be to reduce blood flow
and therefore congestion. Fibrosis develops at the staple
line maintaining the haemorrhoids in their new position.
The main stapling gun in use in the United Kingdom is
the PPH03 (Ethicon Endo-Surgery (Europe) GmbH,
part of the Johnson & Johnson family of Companies,
Norderstedt, Germany), which is used by the majority of
colon and rectum surgeons. Covidien (Covidien, New
Haven, Connecticut, USA) have a dedicated stapling
instrument for haemorrhoidal surgery that is similar indesign to the stapler provided by Ethicon Endo-Surgery. Chex
Healthcare (Chex Healthcare, Frankenman International
Ltd., Kowloon, Hong Kong) is newer to this market and
has produced a stapler that is very similar to the one made
by Johnson and Johnson. There are some key differences:
it is around 40% cheaper and has a design that may make
it easier to use in male patients. SH is conducted using a
stapling gun. Reflecting the pragmatic nature of the trial,
surgeons will be able to use the gun they would normally
use in practice.
Traditional excisional haemorrhoidectomy
There are two main excisional procedures currently carried
out: open (Milligan and Morgan) and closed (Ferguson).
Both have the intention of excising the haemorrhoidal
cushions and are traditionally associated with severe post-
operative pain. The apparent efficacy of the procedures
may be, in part, due to reluctance of patients to seek further
treatment in the light of previous experience. Participating
surgeons are required to have undergone appropriate sur-
gical training and be competent to perform traditional
excisional haemorrhoidectomy (TH).
Subsequent arrangements
Notification of GPs
General practitioners (GP) will be notified by letter, which
includes a GP eTHoS information sheet, that their patient
has been randomised to the eTHoS study. GPs are asked
to phone the Study Office if the participant moves,
becomes too ill to continue with the study, dies, or any
other notifiable event/possible adverse event occurs. Alter-
natively, staff at the study office may contact the GP.
Flagging on central medical databases
Consent will be sought from all participants recruited to
the RCT to be flagged for notification of haemorrhoidal
recurrence. To evaluate long term safety, the partici-
pants will be flagged for further haemorrhoidal surgery
through Hospital Episode Statistics (HES) in England
and Patient Episode Database Wales (PEDW) in Wales and
the Information Services Division (ISD) data in Scotland,
when all participants have reached 12 and 60 months.
Safety
We will report serious adverse events in accordance with
the guidance from the National Research Ethics Service
(NRES), which is a subdivision of the National Patient
Safety Agency.
Possible expected occurrences
In this study a number of potential occurrences are
expected. Possible (expected) intraoperative occurrences
associated with the intervention include anaesthetic re-
lated problems, intra-operative instrument failure, damage
Figure 1 Flow diagram of the eTHoS trial. EQ-5D, European Quality of Life 3 Dimensions; VAS, visual analogue scale; SF36, Short Form (36)
Health Survey.
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occurrences associated with either type of surgery occur-
ring at any time during the trial include haemorrhage,
requirement for blood transfusion, anal stenosis, anal
fissure, pain, urinary retention, residual anal skin tags,
anal fistula, prolapse, difficult defecation, faecal urgency,
wound discharge, pelvic sepsis, systemic complications
and pruritis.
Details of any of the occurrences listed above will be
recorded on the case report forms and participant
completed questionnaires and reported to the data
monitoring committee (DMC).
Procedure for reporting untoward and related serious
adverse events in this study
A serious adverse event (SAE) in the eTHoS trial is defined
as when one of the following events occurs to a research
participant:
1. related (resulted from administration of any of the
research procedures) and
2. expected or unexpected (that is, the type of event
that is not listed above as an expected serious
occurrence) that causes death, is life threatening,
requires hospitalisation, results in significant
incapacity/disability or is otherwise considered
medically significant by the investigators.
All SAEs will be recorded on the Serious Adverse Event
Report form. In addition, SAE forms will record all deaths
due to any cause during the course of the study.
Reporting responsibilities of the chief investigator
When the web-based Serious Adverse Event form is com-
pleted detailing any possible related and unexpected SAEs,
the chief investigator (CI) will be notified automatically. If,
in the opinion of the local investigator and CI, the event is
confirmed as being related and unexpected, the CI will
submit a report to the main REC and the study sponsors
within 15 days of the CI becoming aware of it or within
7 days if it is a death (related to the study).
Measures of outcome
The study has a patient-centred and an economic primary
outcome, and multiple secondary patient-reported, clinical
and economic outcomes.
Primary
The patient-centred outcome is the quality of life profile
over the follow-up period (area under the curve derived
from EQ-5D measurements at baseline, 1 week, 3 weeks,
6 weeks, 12 months, EQ-5D at 18 months only if not
completed at 12 months, 24 months and (subject to
securing further funding) 60 months.The trial economic outcome is the incremental cost
per quality adjusted life year (QALY) gained with QALYs
based on the responses to the EQ-5D at 24 months.
The economic model outcome is the incremental cost
per QALY over the lifetime of the participant.
Secondary
The patient-reported outcomes include the following:
1. generic health profile measured by SF-36 and EQ-5D,
2. visual analogue scale (VAS) pain score,
3. Cleveland incontinence score,
4. haemorrhoid symptom score,
5. post-operative analgesia consumption,
6. recurrence of haemorrhoids, and
7. tenesmus.
Clinical outcomes are perioperative and postoperative
complications including the following:
1. haemorrhage,
2. requirement for blood transfusion,
3. anal stenosis,
4. anal fissure,
5. urinary retention (which requires catheterisation),
6. residual anal skin tags,
7. difficult defecation,
8. wound discharge,
9. pelvic sepsis, and
10. pruritus.
Economic outcomes will be the costs based on resource
use data and include the following:
1. Costs to the NHS and patients at two years
a. time to recovery
b. length of hospital stay
c. use of health services for haemorrhoid related
events or treatments
d. patient costs (treatments, travel to health
services, sick leave)
e. need for alternative management for
haemorrhoids (for example, surgery, drugs)
f. other use of health services
i. visits to GP
ii. visits to practice nurse
iii. visits to colorectal surgeon
2. Estimated lifetime cost to NHS and patient
3. QALYs estimated from the EQ-5D at 24 months
4. QALYs estimated over the patient’s lifetime
5. Cost-effectiveness analysis (incremental cost
per case of stapled haemorrhoidopexy and
traditional haemorrhoidectomy excision
avoided).
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Follow-up will consist of clinical follow-up at 6 weeks
and postal questionnaires at 1 week, 3 weeks, 6 weeks,
12 months (and 18 months if EQ-5D not completed at
12 months), 24 months and (subject to securing further
funding) 60 months, with the main outcome assessment
planned once the 24-month (from the date of random-
isation) follow-up is complete.
Measuring outcomes
In this study the colorectal surgeon and the participant
will know which intervention the participant has received.
Clinical outcomes will be collected by the ROs and the
colorectal surgeons. CRFs can be obtained from the Trial
Office by contacting ethos@abdn.ac.uk. Table 1 shows the
eTHoS schedule for physical assessment/data collection.
Patient reported outcomes
At baseline, (recruitment) participants will complete the
patient reported outcome (PRO) questionnaires. In add-
ition at 1 week, 3 weeks, 6 weeks, 12 months (EQ-5D only
at 18 months if not completed at 12 months), 24 months
and (subject to securing further funding) 60 months, par-
ticipants will complete the eTHoS PRO questionnaires.
These will be distributed by post and completed by the
participant. Participants will be given the option to
complete the 1-week, 3-week, 6-week, 12-month (EQ-5D
only at 18 months if not completed at 12 months), 2-yearTable 1 eTHoS schedule for physical assessment/data collecti
Baseline Surgical
form
1 week 3 weeks 6 w
Clinical status CRF or data ○
Surgical details ○
Patient preference ○
6 weeks clinical follow-up
EQ-5D ○ ●∞ ●∞
SF-36 ○
Pain VAS ●∞ ●∞
Haemorrhoid symptom
score
○
Cleveland incontinence
score
○
Health care utilisation
questions
Travel costs questionnaire
Recurrence
Analgesia question ●∞ ●∞
DCE
Hospital statistics for
further surgery
○ Clinic; ● Postal; x HES, PEDW and ISD; ∞Web based. CRF, case report form; DCE, d
Questionnaire; SF-36, Short Form Health Survey 36 Question form; VAS, visual analoand 5-year participant reported outcome questionnaires
on a secure participant portal within the eTHoS website.
Participants will be provided with a log-in to access the
portal. In the event that these postal questionnaires are
not returned, participants will be telephoned to obtain
the missing data for the 1- and 3-week questionnaires.
A postal reminder will be sent if there is no response to
the 6-weeks, 12-month, 24-month and (subject to secur-
ing further funding) 60-month questionnaires. If they are
not returned, a second reminder will be sent. If question-
naires are returned but not adequately completed, (that is,
key outcome data are missing), either a member of the
study office team or the RO, as appropriate, will telephone
the participant and obtain the missing questionnaire data
as required.
Healthcare utilisation
NHS costs for health services use in both secondary and
primary care by the UK trial participants will be collected.
At 12, 24 and (subject to securing further funding)
60 months after randomisation, participants will provide
information about their use of health services (via the
health care utilisation questions within the eTHoS patient
reported outcome instrument. A postal questionnaire
survey of all participants will be used to ascribe costs to
typical episodes of health service use (the Participant
Travel Cost Questionnaire) sent approximately 27 months
after randomisation. The underlying aim is to keepon
eeks 12 months 18 months 24 months 27 months 60 months
○
○
●∞ ●∞ ●∞ ●∞ ●∞
●∞ ●∞ ●∞ ●∞
●∞
●∞ ●∞ ●∞ ●∞
●∞ ●∞ ●∞ ●∞
●∞ ●∞ ●∞
●∞
●∞x ●∞ ●∞x
●∞
∞ ●
●∞x ●∞x
iscrete choice experiment; EQ-5D, EuroQol Group’s 5 Dimension Health Status
gue score.
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minimise the burden on the participants and the effect
on response rates.
Patient preference (baseline and discrete choice experiment)
Burch and colleagues [6] found that the two treatments
differed in terms of short-term outcomes (earlier return
to usual activities, pain) and differed in terms of the risk
of recurrence. Quality of life measurement (and QALYs
based upon them) may not fully represent patients’
preferences for treatments and their associated out-
comes. Given this, global patient preference will be
elicited at baseline using a single 5-point Likert scale
response to a hypothetical example. Furthermore, a
discrete choice experiment (DCE) to allow an in-depth
elicitation of the individual strength of preference for
the different treatments during the follow-up period will
be conducted. The choice of attributes will relate to the
trial outcome measures and reflect advice from mem-
bers of the trial team, as well as evidence from the ap-
propriate literature. One further attribute of the DCE
will be patient cost, which will allow willingness to pay
(WTP) to be estimated. In particular, willingness to pay
for specific attributes of treatment will be assessed. Esti-
mating willingness to pay from the DCE will enable
these estimates to be combined into the broader economic
evaluation. The DCE will also include an additional surgi-
cal intervention, haemorrhoidal artery ligation (HAL) to
take into account all the treatment options available to
patients with haemorrhoids.
The DCE will describe the intervention in terms of a
number of characteristics (attributes), for example, time
in short-term pain and risk of recurrence. The extent to
which an individual values an intervention will depend
upon the levels of these attributes [12,13]. The DCE
technique involves presenting choices to individuals that
imply a trade-off in terms of the levels of the attributes.
To define the attributes and levels for the DCE, a litera-
ture review will be conducted as well as taking expert ad-
vice on potential attributes from members of the research
team. Once the attributes and levels are defined, experi-
mental design techniques will be used to reduce the num-
ber of possible choice sets to a manageable size, whilst still
being able to estimate utility scores. In addition to the
choices derived from the experimental design, two choice
sets will be added to test the internal consistency of re-
sponses. These will be dominant (better) choices for one
option and respondents would be expected to choose
them.
The questionnaire will be piloted amongst a small
sample (members of the research group and Health
Services Research Unit, Aberdeen) to refine all practical
aspects of the survey and to ensure that respondents
are making trade-offs between the attributes. Once thepilot is complete and the questionnaire refined, a propor-
tion of trial participants (n =100) will be sent the DCE
questionnaire. The questionnaire will be sent to an online
survey panel of non-trial participants. Generalised linear
(for example, logistic) regression models will be used to
analyse the response data. The decision on which statis-
tical model to use to analyse the data is an empirical
one and will depend to a certain extent on the final
data collected.
Data processing
Clinical data will be collected at the individual hospital
centres using, where necessary, hospital-based records
and hardcopy CRF forms. These clinical data will then
be input into the eTHoS database by local researchers
using an electronic web-based data capture system (in
addition, relevant clinical data will be collected from
routine data sources (HES, PEDW & ISD)). Extensive
range and consistency checks will enhance the quality of
the data. Staff in the Study Office will provide periodic
data queries to local research staff to ensure that the
data are as complete and accurate as possible.
Analysis plans
The full details of the statistical analysis plan (SAP) can
be obtained from the Trial Office by contacting etho-
s@abdn.ac.uk.
Ground rules for the statistical analysis
Study analyses will follow the SAP agreed in advance by
the Trial Steering Committee. The main statistical ana-
lyses will be based on all participants as randomised, ir-
respective of subsequent compliance with the treatment
allocation.
The primary outcome, area under the curve (mea-
sured by EQ-5D), will be generated for each participant
using the trapezoidal rule. Missing EQ-5D data will be
estimated using a multiple imputation approach which
makes use of partial outcome data [14]. Sensitivity
analyses will be conducted to assess the robustness
of the treatment effect estimate to these approaches.
The primary outcome measure will be analysed using
linear regression with adjustment for the minimisation
variables. Secondary outcomes will be analysed using
generalised linear models with adjustment for mini-
misation and baseline variables as appropriate. Statis-
tical significance will be at the two-sided 5% level with
corresponding confidence intervals derived. Subgroup
analyses will explore the possible treatment effect
modification of clinically important factors (grade and
gender), through the use of treatment by factor inter-
action, all using a stricter two-sided 1% level of statis-
tical significance.
Watson et al. Trials 2014, 15:439 Page 10 of 17
http://www.trialsjournal.com/content/15/1/439An independent Data Monitoring Committee (DMC)
will meet early in the course of the trial to agree to its
terms of reference and will review confidential interim
analyses of accumulating data.
Timing and frequency of analyses
A single principal analysis is anticipated once the final
participant has reached the 24 months time point. The
DMC will determine the frequency of confidential in-
terim analyses. The potential for analysing longer-term
follow-up data (post 24 months) will be assessed once
the principal analysis has been carried out.
Planned subgroup analyses
Subgroup analyses are planned to investigate the influ-
ence of haemorrhoidal grade and gender.
Economic analysis
Costs of management of haemorrhoids for eTHoS
participants Participant costs will comprise three main
elements: self purchased health care, travel costs for
making return visit(s) to NHS health care, and time
costs of travelling and attending NHS health care.
Self-purchased health care is likely to include items
such as prescription costs and over-the-counter medica-
tions. Information about these will be collected through
the healthcare utilisation questions.
Estimation of travel costs requires information from
participants about the number of visits to, for example,
their GP or consultant (estimated from the healthcare
utilisation questions) and the unit cost of making a
return journey to each type of healthcare provider (from
the Participant Unit Cost Questionnaire).
The cost of participant time will be estimated in a
similar manner. The participant will be asked, in the
Participant Unit Cost Questionnaire, how long they
spent travelling to and attending their last visit to each
type of healthcare provider. Participants will also be
asked what activity they would have been undertaking
(for example, paid work, leisure, or housework) had they
not attended the healthcare provider. These data will be
presented in their natural units (for example, hours)
and also as cost estimates using standard economic
conventions (for example, the Department of Transport
estimates for the value of leisure time). These unit time
costs, measured in terms of their natural and monetary
terms, will then be combined with estimates of the num-
ber of healthcare contacts derived from the healthcare
utilisation questions.
Costs of intervention The costs of the surgical inter-
ventions will be recorded on a per patient basis. The
resources used to provide surgery will be calculated by
consulting with relevant staff (surgeons, theatre nurses,business managers) and members of the trial team to
elicit information on the following:
1. reusable equipment,
2. frequency of use of that equipment,
3. consumables used during surgery,
4. staff mix of the surgical team and
5. overheads costs for specific time periods.
In addition to this, the operative details will be collected
on the CRFs and will provide estimates of the grade of
operator, assistant and anesthetist, as well as relevant
procedure times.
Unit costs for these resources will be based on nation-
ally available data and study-specific estimates. Longer
term estimates of resource use and cost will be derived
from trial estimates and the literature.
Length of stay information will be elicited for each
patient through the case report forms by collecting the
date of admission and discharge. Unit costs for each
level of care will be initially obtained from the Scottish
Health Service Costs (SHSC) [15] for the primary analysis
and NHS National Reference Costs in a secondary analysis.
These sources will not have a cost per day for all hospital
services; therefore some calculations will be needed to
determine the ‘cost per day’ for each level of care.
Costs of subsequent care The number of outpatient
visits per patient for each relevant specialty will be ob-
tained from the CRFs. Unit costs for outpatient visits
will initially be obtained from the SHSC [15] for the pri-
mary analysis and National Reference Costs in the sensi-
tivity analysis [16].
The number of general practice contacts, for example
GP office or home visits or phone consultations, will be
obtained from the Health Service Utilisation Question-
naire. Unit costs for GP visits will be obtained from the
Personal Social Services Research Unit (PSSRU) unit costs
of community care [16]. For each patient, the number of
visits will be multiplied by the appropriate unit cost. These
costs will be summed to produce a total cost per patient.
When a cost for each patient has been estimated, a mean
cost for each intervention group will be calculated.
Any reoperations or new surgical interventions will
be identified from the CRFs and for the associated cost
estimated using data from routine data sources [15,16]
or operation costs previously estimated for the study.
Any duration of any relevant admissions during the
follow-up period will be estimated from the CRFs and
the associated cost estimated using the methods de-
scribed above.
Cost effectiveness As part of this study, an economic
evaluation will be conducted. It will be based on both a
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existing, or de novo, economic model will be used to
assess the relative cost-effectiveness (assessed in terms
of incremental cost per QALY) and net benefits of SH
and TH. A model was developed as part of a recent
HTA-funded project, and we have negotiated access to
that model [6]. Our group has also developed a model to
compare the cost-effectiveness of SH and RBL for grade
II haemorrhoids. We will critique these models and use,
or adapt them, to address our study question. If necessary
we will use the lessons learnt from these models to
develop a new model that better addresses the research
question. The data from the trial will be the main source
of data for the modelling but further data with which to
model outcomes beyond a 24-month follow-up will be
systematically derived from the literature and other exist-
ing data sources following guidance for best practice [17].
Data collection from the trial will focus on estimating
the use of secondary and primary care resource use and
on health state valuations obtained from EQ-5D. Resource
use and patient costs will be obtained from participant-
completed questionnaires at 12 and 24 months. Unit cost
will be based on nationally available data and study-
specific estimates. Longer term estimates of resource use
and cost will be derived from trial estimates and a struc-
tured review of the literature. QALYs will be estimated
from the responses to the EQ-5D valued using the UK
population tariffs.
The results of the economic model will be supple-
mented by a within-trial analysis. This analysis will use
the estimates of costs and QALYs estimated for each trial
participant to calculate the incremental cost-effectiveness
ratios for the 24-month follow-up, and where appropriate,
the analysis will mirror the statistical analysis (for ex-
ample, incremental costs and QALYs will be adjusted for
the minimisation variables using regression techniques).
To facilitate interpretation of the trial results, the within-
trial economic analysis will also be presented in the form
of a balance sheet where differences in terms of benefits
and costs of the two trial interventions are presented in
their natural or clinical units.
The perspective of the model and within-trial analyses
will be the patient and the UK NHS. The results of the
analyses will be presented as point estimates of mean in-
cremental costs, effects and incremental cost per QALY.
Sensitivity analysis will be applied to the model in order
to assess robustness of the results to realistic variations
in the levels of the underlying data and also alternative
assumptions, for example, QALYs derived from the SF-
36. This will be accomplished using probabilistic and
deterministic sensitivity analyses to address parameter
and other forms of uncertainty. Similarly, for the within-
trial analysis, techniques such as bootstrapping will be
used alongside deterministic sensitivity analyses to addressuncertainty. In both the model and the within trial ana-
lyses the cost per QALY data will be presented in terms of
cost-effectiveness acceptability curves (CEACs).
Discrete Choice Experiment analysis The results of
the DCE will be combined with the clinical outcomes
estimated from the trial or model to provide an estimate
of the mean WTP for each intervention considered for
both the model based and the within trial analyses.
Results will be presented as incremental net benefits
(Net benefits = mean WTP - mean cost for each inter-
vention). The intervention with the greatest net benefit
would be considered the most efficient. For the model-
and trial-based analyses, probabilistic, or stochastic (for
the trial based analysis), along with deterministic sensi-
tivity analyses, will be constructed.
Sample size and feasibility
Sample size sought
A sample size of n =338 per group is required to provide
90% power to detect a difference in the mean area under
the curve (AUC) of 0.25 standard deviations derived
from EQ-5D score measurements, with a significance
level of 5% (two-sided alpha). Good data on 24-months
AUC for this instrument in this patient group is sparse,
but a 0.25 effect size has often been shown to correspond
to a worthwhile difference in quality of life measures.
This would equate to a difference of 0.1 in the AUC
(QALY) assuming a standard deviation of 0.4.
Evidence-based strategies will be used to enhance ques-
tionnaire response rates in this highly motivated group
of patients. Conservatively, to allow for 15% non-response
in the outcome, it is proposed to randomise 400 subjects
in each of the two groups. Such a sample size would
provide 90% power to assess differences in the secondary
outcome of recurrence between the two surgical tech-
niques from around 10% to around 4%. This magnitude of
difference is supported by a recent systematic review
which showed a non-statistical trend higher recurrence in
the SH group compared to TH group [4].
Recruitment rates
Previous experience of recruitment in NIHR/MRC surgery
trials co-coordinated from the trial office, suggests that
around 50% of those eligible will agree to be randomised.
The recruitment period is anticipated to last 43 months
(months 4 to 46 inclusive). Around 1,600 eligible patients
are likely to have to be approached to randomise the
required 800.
Organisation
It is anticipated that there will be bi-annual PMG, six
meetings of the TSC and five of the DMC. Two meet-
ings are planned for collaborators (including the
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when all the centres have been identified and the second
when results are available.
Local organisation in centres
Lead colorectal surgeon Each collaborating centre will
identify a lead colorectal surgeon (principal investigator
(PI)) who will be the point of contact for that centre.
The PI will take responsibility for ensuring that the
outcome measures are taken consistently and in line
with the standardised protocols developed for the study.
Specifically, this person will do the following:
1. accept overall responsibility for the eTHoS study
locally;
2. assist the eTHoS study office in establishing the
study locally (for example agreement from clinical
colleagues, helping the main study office to facilitate
local trust approval, identify and appointing an RO
and informing all relevant local staff about the study);
3. identify eligible patients;
4. explain the eTHoS study and take informed consent;
5. take overall lead responsibility for ensuring that the
outcome measures are taken consistently and in
line with the standardised protocols developed for
the study;
6. take overall lead responsibility for all clinical aspects
of the study locally (for example, if any particular
concerns occur);
7. notify the eTHoS study office of any unexpected
clinical events which might be related to study
participation;
8. provide support and supervision for the local RO;
9. represent the centre at the collaborators’ meeting;
10. place patients who are randomised to SH or TH on
the waiting list for surgery;
11. complete fully the appropriate eTHoS paperwork
for patient participation; and
12. facilitate/supervise/participate in the upload
of this hardcopy patient data to the web based
system.
Recruitment officer (RO) at each centre Each collab-
orating centre will appoint a RO to organise the day to
day running of the study in that centre. The overall respon-
sibilities of this person will be as follow:
1. work with the PI and other local colorectal surgeons
in order to organise the day to day recruitment
and follow-up of eTHoS participants of the study in
that centre;
2. keep regular contact with the PI and other
colorectal surgeons, notifying them of any problem
or unexpected development;3. maintain regular contact with the Study Office
(including mailing of relevant material to the
Study office);
4. keep local staff informed of progress in the study;
5. organise and supervise alternative recruiters in case
of holiday or absence; and
6. represent the centre at the collaborators’ meeting if
required.
The specific responsibilities of this person will be as
follows:
1. Assist the PI and other local colorectal surgeons to
keep a log of whether eligible participants are
recruited or not (with reasons for non-participation)
2. Assist the PI and other colorectal surgeons in the
distribution of the Patient Information Sheet and the
collection and organisation of the patient consent
forms
3. As appropriate organise follow-up to consultation
appointments at 6 weeks after surgery with eTHoS
participants
4. Ensure timely processing of consent and patient
data (complete on-line baseline and follow-up
clinical-data collection forms and enter into web
application)
5. Undertake baseline measurements and follow-up
measurements as appropriate and in accordance
with eTHoS standard operating procedures
6. Support completion (as appropriate) of research
questionnaires with the patients both face to face
(at baseline) and when required during follow-up,
including over the telephone as indicated from the
eTHoS Study Office (that is, in the case of non
return or significant missing data)
7. Act as a point of contact for the participants at all
times and provide information about the trial, as
necessary.
Study co-ordination in Aberdeen
The study office team The Study Office is in the Centre
for Healthcare Randomised Trials (CHaRT) based within
the Health Services Research Unit, University of Aberdeen
and provides day to day support for the clinical centres.
The trial manager in CHaRT at Aberdeen will take re-
sponsibility for the day-to-day transaction of study activ-
ities. The data co-ordinator will provide clerical support
to the trial, including organising all aspects of the postal
questionnaires (mailing, tracking, and entering returned
data using the study web data entry portal). The senior
IT manager will oversee all IT aspects of the study,
while the senior trials manager will provide mentoring
and guidance to the trial manager and advice to the
team on generic coordination issues. The programmer
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grammes for the trial, including the randomisation ap-
plication and all administrative and analysis databases.
The trial statistician, under the supervision of a senior
statistician, will be responsible for transacting all statis-
tical elements of the study (including contributing to
the pre-specified SAP and writing the statistical code
that will implement this SAP, and producing progress
reports for all the study committees (including the TSC
and DMC). The economist, under the supervision of a
senior economist, will take responsibility for all aspects
of the economic evaluations integral to the study. The
CHaRT quality assurance manager will ensure that
CHaRT’s standard operating procedures for trials have
been followed and properly documented, including
observance of GCP throughout. At the centres, the re-
cruitment coordinators will be responsible for all local
processes involved in identifying, consenting and rando-
mising the participants, along with facilitating the delivery
of the intervention, under the supervision of the lead colo-
rectal surgeon.
The eTHoS study office team will meet formally at
least monthly during the course of the study to ensure
smooth running and trouble-shooting. Finally, we intend
to produce a yearly eTHoS Newsletter for participants
and collaborators to inform everyone of progress and
maintain enthusiasm.The project management group
The study is supervised by its project management group
(PMG). This consists of the grant holders and representa-
tives from the Study Office. Observers may be invited to
attend at the discretion of the PMG. The PMG will meet/
teleconference every six months on average.
The research team has the expertise to cover the clinical
and surgical aspects of the research. All the consultant
surgeons involved have extensive surgical experience of
stapled haemorrhoidopexy. Messrs Loudon (Cochrane
review), Jayne (HTA systematic review) and Watson
have experience in the design and conduct of RCTs
involving SH. Messrs Loudon, Jayne, Maw and Brown have
published extensively on SH. Messrs Watson, Loudon,
Jayne and Brown are SH trainers.The trial steering committee
The study is overseen by an independent trial steering
committee. The other members are the grant holders.
Observers or members of the host university (Aberdeen)
and the funders (HTA) may also attend, as may other
members of the PMG or members of other professional
bodies at the invitation of the chair. Terms of reference
for the TSC can be accessed upon request from the
eTHoS study office.Research governance, data protection and sponsorship
Research governance The trial will be conducted accord-
ing to the principles of good clinical practice provided by
the MRC guidelines, the detail of which can be viewed at
the following link: http://www.mrc.ac.uk/documents/pdf/
good-clinical-practice-in-clinical-trials/ or in line with
local implementation of research governance to at least
the standard of the Aberdeen University policy on re-
search governance, which can be viewed at the following
link: http://www.abdn.ac.uk/staffnet/governance/research-
governance-278.php.Data protection The trial will comply with the Data
Protection Act 1998 and regular checks and monitoring
are in place to ensure compliance. Data are stored
securely in accordance with the Act and archived to a
secure data storage facility. The senior IT manager (in
collaboration with the CI) will manage access rights to
the data set. Prospective new users must demonstrate
compliance with legal, data protection and ethical
guidelines before any data are released. We anticipate
that anonymised trial data will be shared with other re-
searchers to enable international prospective meta-
analyses.
All data collected and stored within the study will
comply with the Data Protection Act.
The Health Services Research Unit, University of
Aberdeen Protecting Information Policy will be adhered
to and can be accessed via this link: http://www.abdn.
ac.uk/hsru/documents/Protecting_information_policy_v5_-
Dec13.pdf.Sponsorship NHS Highland and the University of
Aberdeen are the co-sponsors for the trial.Data and safety monitoring
Data monitoring committee A separate and independent
data monitoring committee (DMC) will be convened. A
copy of the DMC charter can be obtained by contacting
the Trial Office on ethos@abdn.ac.uk. It is anticipated that
the members will meet once to agree terms of reference
and on at least three further occasions to monitor accu-
mulating data and oversee safety issues. This committee
will be independent of the study organisers and the TSC.
During the period of recruitment to the study, interim
analyses will be supplied, in strict confidence to the DMC,
together with any other analyses that the committee may
request. This may include analyses of data from other
comparable trials. In the light of these interim analyses,
the DMC will advise the steering committee if, in its view,
there are any ethical or safety issues that may necessitate
modification to the protocol or closure of the trial.
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staff (except those who supply the confidential analyses)
will remain ignorant of the interim results.
The frequency of interim analyses will depend on the
judgement of the Chairman and other independent DMC
members. We anticipate that there might be two interim
analyses and one final analysis.
Safety concerns Haemorrhoidal surgical treatment is a
very common surgical procedure performed routinely
by colorectal surgeons. However, as with all colorectal
surgery, there are potential complications (see section
on Safety), and these will be carefully monitored through-
out the study.
In terms of general hazards of undertaking a large
multi-centre RCT, all of (i) the safety of the participants,
(ii) the scientific integrity of the study, and (iii) value for
money for the public funder has been safeguarded by
having the following: (a) a formal Clinical Trial Risk
Assessment carried out by the University of Aberdeen
and NHS Highland in their role as sponsors, (b) an
excellent track record of the applicants in delivering suc-
cessful multi-centre trials, (c) the support of a dedicated
UKCRC registered Trials Unit (CHaRT at University of
Aberdeen) and (d) excellent governance of the trial con-
duct by an experienced internationally recognised TSC
and DMC.
Collaborators and participants may contact the chairman
of the TSC through the study office about any concerns
they may have about the study. If concerns arise about pro-
cedures, participants or clinical or research staff (including
risks to staff), then these will be relayed to the Chairman of
the DMC.
Ethical approval
The North of Scotland Research Ethics Committees
reviewed and approved this study on 18th June 2010
(REC reference number, 10/S0802/17).
Important amendments to this protocol will be com-
municated via email or letter as appropriate to the rele-
vant parties (for example, sponsors, REC, participants,
collaborators, trial registry).
Discussion
The eTHoS study is the largest ever, randomised controlled
trial on benign ano-rectal disease [18]. The trial is designed
to answer an important question regarding the clinical and
economic effectiveness of two surgical operations for
haemorrhoids. Haemorrhoidal disease is very common
in the developed world, and around 29,000 operations
are performed in the UK on an annual basis [6].
Both operations have been available for over 15 years, but
there has never been a rigorously conducted, large-scale,
multicentre evaluation comparing both interventions. Thisis frequently the case when surgical technology is intro-
duced into the market. Devices and operations penetrate
practice through insidious adoption without due diligence
being performed. This trial is designed to assess whether
the newer operation, stapled haemorrhoidopexy, is more or
less effective and cost-effective than the traditional surgery
of excisional haemorrhoidectomy.
Surgical interventions are being continuously designed
and the eTHoS trial is being run concurrently with
other multicentre RCTs on haemorrhoid disease. The
HubBLe trial [19] (of which the CI is a co-applicant) is
comparing haemorrhoidal artery ligation with rubber
band ligation for grade II and III haemorrhoids, whilst
the LIGALONGO trial [20] being conducted in France
is randomising between stapled haemorrhoidopexy and
Doppler-guided arterial ligation with mucopexy [21]. These
three multicentre RCTs are concurrently comparing the
clinically relevant surgical interventions for haemorrhoids
at the same time.
Whilst the running of parallel evaluations is exciting,
it also presents a challenge to recruitment, as several
recruiting centres are randomising patients to both trials
within the UK. The adoption of HAL within surgical
practice, prior to rigorous evaluation, has also had an
impact on recruitment, as surgeons are keen to adopt and
trial new surgical technologies. As such, the trial has been
slower to recruit than originally expected. The recruit-
ment period was therefore extended by 15 months to
accommodate the short fall. At the time of publication,
over 750 participants have been randomised in the trial.
The fundamental trial outcomes remain unchanged;
however, there have been a number of amendments to the
conduct of the trial, since its inception. The majority of
these have centred on patient retention and follow-up. It is
essential to the conduct of the trial that the questionnaire
response rate is high. We introduced several initiatives dur-
ing the recruitment period including a within-trial study,
called to incentivise or not to incentivise. We aimed to test
the null hypothesis that incentivisation would make no dif-
ference to questionnaire return rate. Participants were ran-
domised to receive a five pound Sterling voucher with
their 12- and 24-month follow-up questionnaires on the
assumption that monetary incentivisation had worked in
other trials [22].
Potential eTHoS trial participants were also invited to
be involved in a further methodology project. This study
sought to prospectively measure potential trial partici-
pant’s readiness to participate in a RCT. It is being con-
ducted across a range of different clinical conditions and
trials and seeks to evaluate how well informed patients
feel before making a choice to participate in a trial.
Quality of life assessments may not completely represent
patients’ preferences for treatment and their associated out-
comes. We therefore planned a discrete choice experiment
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what factors are important for potential patients, when they
are offered a variety of therapy options. The choices include
potential complications (for example, pain, bleeding, and
recurrence) and how much money a participant would be
willing to pay for a procedure. We included the three most
currently performed surgeries, excisional haemorrhoid
surgery, stapled haemorrhoid surgery and haemorrhoidal
artery ligation.
eTHoS is a large surgical trial that will enable the
effectiveness and cost-effectiveness of SH and TH to be
assessed. Taken together with HubBLe and LIGALONGO,
the three multicentre trials will help inform patients, clini-
cians and health commissioners about the clinical utility
and outcomes of competing treatments for haemorrhoids.
It is hoped that in the future it will be possible to stratify
treatment according to patient characteristics based on
more robust evidence.
Availability of the protocol
The full protocol can be obtained from the funder on
the following link
http://www.nets.nihr.ac.uk/projects/hta/082402
This protocol has been prepared in accordance with
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT), a completed checklist is provided
as Additional file 1. In accordance with the SPIRIT
guidelines, the eTHoS authorship policy is provided in
Additional file 2 while the eTHoS participant consent
form and patient information leaflet are provided in
Additional file 3.
Ancillary studies
It is recognised, that the value of the study may be en-
hanced by smaller ancillary studies of specific aspects.
Plans for these will be discussed in advance with the
PMG. REC approval will be sought for any new pro-
posals, if appropriate.
Indemnity
The Patient Information Sheet provides the following
statement regarding indemnity for negligent and non-
negligent harm:
‘We do not expect any harm to come to you by taking
part in this study. However, if you are harmed by taking
part in this research project, there are no special com-
pensation arrangements. If you are harmed due to some-
one’s negligence, then you may have grounds for a legal
action but you may have to pay for it. Regardless of this,
if you wish to complain, or have any concerns about any
aspect of the way you have been approached or treated
during the course of this study, the normal National
Health Service complaints mechanisms (which includesprofessional indemnity insurance) would be available to
you’.
In addition, the universities involved with this study
hold and maintain a ‘no fault’ insurance policy. This pol-
icy covers all employees of the universities and those
working under their direction.
Data sharing and preservation
The applicants will comply with the data sharing and
preservation guidance. The trial statistician (in collab-
oration with the CI) will manage access rights to the
data set. Prospective new users must demonstrate com-
pliance with legal, data protection and ethical guide-
lines before any data are released. We anticipate that
anonymised trial data will be shared with other re-
searchers in the future to enable meta-analyses.
Publication
The success of the study depends entirely on the whole-
hearted collaboration of a large number of participants,
as well as clinicians, including colorectal surgeons and
ROs. For this reason, chief credit for the study will be
given, not to the committees or central organisers, but
to all those who have collaborated in the study. The
results of the study will be reported first to study collab-
orators. The main report will be drafted by the project
management group and circulated to all clinical coordi-
nators for comment. The final version will be agreed by
the TSC before submission for publication, on behalf of
all the eTHoS collaborators.
To safeguard the integrity of the main trial, reports of
ancillary or satellite studies will not be submitted for
publication without prior agreement from the PMG.
We intend to maintain interest in the study by publi-
cation of eTHoS newsletters at intervals for participants,
staff and collaborators. Once the main report has been
published, a lay summary of the findings will be sent in
a final eTHoS Newsletter to all involved in the trial.
Trial status
The first participant was recruited in January 2011 and the
trial is currently open to recruitment in 29 UK centres.
Additional files
Additional file 1: SPIRIT checklist.
Additional file 2: eTHoS Authorship Policy.
Additional file 3: Study Participant Consent Form and Patient
Information Leaflet.
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